Agios Pharmaceuticals reported $37.84M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Astellas Pharma JPY 337.89B 6.87B Jun/2026
AstraZeneca USD 6.93B 362M Jun/2026
Bayer EUR 11.97B 43M Jun/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Daiichi Sankyo JPY 733.05B 40.68B Jun/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Exelixis USD 29.87M 1.14M Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.1B 116M Sep/2026
Novartis USD 6.1B 182M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026